CHF Solutions Continues Physician-Led Webinar Series with Focus on Treatment of Fluid Overload in Pediatric Patients
July 14 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
improving the lives of patients suffering from fluid overload,
today announced key takeaways from a recent webinar where David
Askenazi, M.D. MSPH shared his experience and perspectives on the
treatment of fluid overload in pediatric patients weighing more
than 20 kg.
Dr. Askenazi is the Director of the Pediatric and Infant Center
for Acute Nephrology (PICAN) at Children’s of Alabama, the
pediatric hospital affiliated with University of Alabama at
Birmingham. Dr. Askenazi is a forerunner in pediatric kidney
support therapy and author of dozens of clinical papers on managing
fluid balance and providing kidney support in pediatric patients.
He has created and hosts the Neonatal and Infant Course on Kidney
Support (NICKS) at Children’s of Alabama.
Clinically important observations made by Dr. Askenazi during
the webinar include:
- In pediatric patients, fluid overload is a common problem
impacting morbidity and mortality, and fluid overload is associated
with multiple conditions, such as heart surgery, nephrotic
syndrome, congenital heart disease, kidney disease, solid organ and
bone marrow transplants, sepsis and severe burns.
- Addressing fluid overload and initiating treatment early
optimizes outcomes in pediatric patients; therefore, fluid volume
should be reported and monitored as a critical vital sign, similar
to other vital signs.
- To assess fluid overload, fluid volume status should be
considered in light of the phases of therapy: rescue, optimization,
stabilization and de-escalation.
- Treatment options for fluid overload include medical
management, fluid restriction and diuretics and ultrafiltration
(aquapheresis).
- While a majority of ICU patients receive diuretics to treat
fluid overload, multiple studies have shown limited direct
improvement in clinical outcomes.1
- Ultrafiltration provides an early alternative therapy to be
considered when medical management fails to achieve fluid balance.
Repeating traditional therapies may harm the patient.
- Alternative fluid removal therapies include peritoneal
dialysis, continuous renal replacement therapy (CRRT), intermittent
hemodialysis and ultrafiltration. Each therapy has advantages
depending on the condition and treatment goals for the
patient.
- Ultrafiltration with the Aquadex system is simple, easy to set
up and provides flexibility to address the needs of the
patient.
- In a retrospective, multi-center study, 32 critically ill
pediatric patients weighing over 20 kgs and predominantly suffering
from hypervolemia were treated with the Aquadex FlexFlow System and
97% (31/32) survived to the end of therapy with minimal
complications associated with the system.2
“Ultrafiltration is a safe and effective therapy for removing
fluid in pediatric patients weighing more than 20 kg,” said Dr.
Askenazi. “The therapy is a helpful and complementary fluid
management tool offering high benefits at a low risk for patients.
Pediatric patients can be very delicate and having a gentle and
flexible option on hand can improve the quality of care provided to
fluid overloaded children.”
“Since the FDA clearance of the Aquadex SmartFlow for eligible
pediatric patients, pediatric hospitals across the country have
recognized the benefit of utilizing gentle ultrafiltration in these
patients,” said John Erb, CEO of CHF Solutions. “Physicians like
Dr. Askenazi are leading the way in creating awareness of
life-saving therapies for the treatment of fluid overload in our
most fragile patients, and we’ll continue to support educational
opportunities that can have a positive impact on patient
outcomes.”
The replay of the webinar is available at
https://ir.chf-solutions.com/events and
https://www.youtube.com/watch?v=sMIF5x5qqvY
About Fluid Overload in Pediatric PatientsFluid
overload (hypervolemia), which occurs when there is too much fluid
in the body, is a major issue among critically ill children and
adults, and when left untreated, it can lead to life-threatening
consequences. Available therapies require very high relative
extracorporeal blood volumes, which can be challenging for
pediatric patients. In a retrospective, multi-center study, 32
critically ill pediatric patients weighing over 20 kgs and
predominantly suffering from hypervolemia were treated with the
Aquadex FlexFlow System and 97% (31/32) survived to the end of
therapy.2
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
About CHF Solutions CHF Solutions, Inc. (CHFS)
is a medical device company dedicated to changing the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the clinical
outcomes associated with the treatment of fluid overload in
pediatric patients. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, the
risks associated with our expectations regarding the potential
impacts of the COVID-19 pandemic on our business operations, the
risks associated with our ability to execute on our commercial
strategy, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, our post-market
clinical data collection activities, benefits of our products to
patients, our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
- https://pubmed.ncbi.nlm.nih.gov/18382190/
- https://pubmed.ncbi.nlm.nih.gov/31462396/
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024